Inflammatory bowel diseases (Crohn's disease and ulcerative colitis) are chronic inflammatory disorders that are often progressive and disabling, predominantly affecting a young population, and associated with significant impact on the quality of life and a high financial burden. The variable phenotypes of IBD with their highly individual disease course make the management of these diseases with complex pathophysiology a clear challenge in clinical practice. Clinical guidelines developed by a number of expert associations and organizations have attempted to streamline and guide these management principles. Although commendable, these guidelines are complex, long, and extensive (23 pages long for CD and 15 pages for UC), lumping the simplistic and the overly complex. Further, these guidelines are often based on lower level of evidence of case-controlled studies, case series, and expert opinion (<50% of the boxed statements in the last published ECCO management guidelines for CD are of level 1 or 2 evidence).
A number of controversial issues continue to surface in the management of patients with IBD. In this special issue of Inflammatory Intestinal Diseases, selected experts provide the latest evidence-based updates and personal opinion weighing in on a number of selected controversies. These include the following: (1) “The Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?” by Drs. Sharara and Malaeb (Lebanon), Lenfant and Ferrante (Belgium) makes a case for the adoption of a novel endoscopic score in UC for assessment of both disease severity and extent, given the often-patchy response and the critical therapeutic decision process that hinges on this assessment; (2) “Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?” by Drs. Murayama, Ma, Panaccione, and Kotze (Canada) who advocate an individualized approach, including arguments for and against early surgery, based on disease characteristics, phenotype, risk factors, and personal preference; (3) “Surgical Techniques and Risk of Postoperative Recurrence in CD: A Game Changer?” by Drs. Luglio (Italy) and Kono (Japan), addresses the impact of early surgery and of specific surgical techniques, such as the Kono-S anastomosis or a “mesentery-based surgery,” on the natural history of the disease, including the possibility to prevent postoperative recurrences; (4) “5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?” by Drs. Herfath (USA) and Vavricka (Switzerland) suggests that the role of 5-ASA as chemoprophylaxis has waned in the era of biologics and small molecule particularly when endoscopic healing is achieved highlighting the goal of proper control of mucosal inflammation to minimize cancer risk; (5) “The Pros and Cons of Mucosal Healing in Crohn's Disease: Bull's Eye or Bust?” is discussed in 2 tandem articles by Drs. O'Morain, Stack, and Doherty (Ireland), and Drs. Mosli and Alameel (Saudi Arabia), and Sharara (Lebanon), highlighting the importance of mucosal healing as a target recognizing the low therapeutic ceiling with current therapies in CD, and arguing for a personalized endoscopic target; (6) “Proactive versus Reactive Therapeutic Drug Monitoring (TDM): Why, When, and How?” by Drs. Shmais and Hashash (Lebanon) and Regueiro (USA) revisits the importance of reactive TDM as a valuable tool in therapy optimization and reviews the emerging role of proactive TDM in some selected patient populations and practice settings; and (7) “The Pros and Cons of Stopping Anti-TNF in CD Remitters” is tackled in 2 tandem articles by Dr. Kobayashi (Japan) and Dr. Louis (Belgium) who review and discuss the evidence regarding a common question raised by patients and practitioners alike.
We believe this special issue written by experts from around the world provides an up-to-date resource on some important controversial and emerging questions in IBD. Although some of these questions and controversies remain unanswered, we believe this set of focused critical reviews of the evidence are useful for the GI generalist and the IBD expert alike, leading to the betterment of patient care. After all, evidence-based medicine is much more than randomized controlled trials. It is the result of a dynamic interplay between relevant scientific knowledge, clinical judgement, experience, and patient values and preferences.
Ala I. Sharara, Beirut.
Conflict of Interest Statement
The author has no conflicts of interest to declare.
